Status:
COMPLETED
Aquagenic Pruritus in Myeloproliferative Neoplasms
Lead Sponsor:
University Hospital, Brest
Conditions:
Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms. Prospective work based on the distribution of a dedicated questionnaire.
Detailed Description
Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis. Distrib...
Eligibility Criteria
Inclusion
- Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
- Suffering (or having suffered) from aquagenic pruritus.
- No age limit, but major
- Patient having formulated his non-opposition
Exclusion
- Patients with MPN with non-aquagenic pruritus,
- Patients with another hematologic disease and aquagenic pruritus
- Patients unable to complete the questionnaire.
- Patients with physical or mental disabilities to formulate non-opposition
- Refusal of participation
Key Trial Info
Start Date :
July 9 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 6 2021
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT04018209
Start Date
July 9 2019
End Date
January 6 2021
Last Update
November 1 2024
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
05
Lyon, Auvergne Rhônes-alpes, France, 69000
2
10
Quimper, Brestagne, France, 29000
3
11
Morlaix, Brittany Region, France, 29600
4
09
Saint-Brieuc, Brittany Region, France, 22000